Waters Aktie

https://finance.yahoo.com/news/waters-corporation-nyse-wat-reports-110000672.html Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currency Instruments grew 8% and recurring revenue grew 9% in constant currency, as growth accelerated across all three reported regions Pharma grew 10% in constant currency, reflecting stronger-than-expected year-end spending dynamics and broad-based growth across the Americas, Europe, and Asia GAAP EPS of $3.88; non-GAAP EPS of $4.10 grew 13% as strong operational performance and better-than-expected sales volume offset foreign exchange headwinds Full-Year 2024 Sales exceeded guidance at $2,958 million, flat as reported and in organic constant currency GAAP operating income margin of 27.9%; operational excellence drove adjusted operating income margin expansion to 31.0%, effectively neutralizing the challenges posed by foreign exchange headwinds GAAP EPS of $10.71; non-GAAP EPS of $11.86 grew 1% versus 2023, which includes a 5% impact due to foreign exchange headwinds Generated $762 million in operating cash flow; $744 million in free cash flow, representing 25% of full-year sales, and a free cash flow to adjusted net income ratio of 105% MILFORD, Mass., Feb. 12, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the fourth quarter and full-year 2024. Sales for the fourth quarter of 2024 were $873 million, an increase of 6% as reported, compared to sales of $819 million for the fourth quarter of 2023. Currency translation decreased sales by 2%. On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2024 was $3.88, compared to $3.65 for the fourth quarter of 2023. On a non-GAAP basis, EPS increased by 13% to $4.10, compared to $3.62 for the fourth quarter of 2023. This includes a decline of approximately 9% due to foreign exchange headwinds, which were 6% or $0.23 adverse to guidance. "We delivered excellent results in the fourth quarter, led by double-digit growth in Pharma, while instruments and recurring revenue both grew high single-digits in constant currency," said Dr. Udit Batra, President & CEO, Waters Corporation. "Growth accelerated across all regions, driven by strong adoption of new products and the success of our strategic initiatives."

David Driscoll discusses Waters Corp https://www.bnnbloomberg.ca/video/david-driscoll-discusses-waters-corp~2136955

https://www.waters.com/nextgen/de/de.html?locale=de_DE https://de.marketscreener.com/WATERS-CORPORATION-14845/?type_recherche=rapide&mots=wat https://www.waters.com/waters/de_DE/Investors/nav.htm?cid=134614445&locale=de_DE

Logo Waters Corporation Designs, manufactures, sells and services analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis Waters Corp. is an analytical instrument manufacturing company, that primarily designs, manufactures, sells and services, high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. It operates through two divisions: Waters Division and TA Division. The Waters division designs, manufactures, distributes and services high performance liquid chromatography and ultra performance liquid chromatography instruments, columns and other chemistry consumables that can be integrated and used along with other analytical instruments. TA Instruments division designs, manufactures, distributes and services thermal analysis, rheometry and calorimetry instruments. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA http://de.4-traders.com/WATERS-CORPORATION-14845/fundamentals/